Safety and biodistribution of intrathecal administration of mesenchymal stem cells (MSCs) and neurotrophin-releasing nanoparticles in a porcine CSF-guided delivery model for amyotrophic lateral sclerosis (ALS) drug discovery.

Intrathecal and intramuscular autologous BM-MSCs have been reported to slow disease progression by increasing neurotrophic factors and reducing inflammatory CSF biomarkers in rapidly progressing patients, although some trials did not reach statistical significance 38 .

also in 111,027 other papers